A Case of Rivaroxaban Associated Intracranial Hemorrhage

Rivaroxaban is a newer anticoagulant initially approved by the Food and Drug Administration to treat nonvalvular atrial fibrillation. Rivaroxaban has several characteristics that are more favorable than warfarin. One of the characteristics is decreased risk of hemorrhage. We report one of the first...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Jean Chin-Yu, Gerona, Roy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Department of Emergency Medicine, University of California, Irvine School of Medicine 2014
Materias:
Diagnostic Acumen
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100836/
https://www.ncbi.nlm.nih.gov/pubmed/25035736
http://dx.doi.org/10.5811/westjem.2014.2.19440
Descripción
Sumario:Rivaroxaban is a newer anticoagulant initially approved by the Food and Drug Administration to treat nonvalvular atrial fibrillation. Rivaroxaban has several characteristics that are more favorable than warfarin. One of the characteristics is decreased risk of hemorrhage. We report one of the first case reports of severe intracranial hemorrhage associated with rivaroxaban in an elderly patient with decreased renal function. We aim to alert emergency medicine providers regarding the likelihood of encountering these patient as newer anticoagulants rise in popularity.

Ejemplares similares